Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.69 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.69 |
| ▸ | RAB9A | P51151 | 6/20 | 0.60 |
| ▸ | NPC1 | O15118 | 5/20 | 0.60 |
| ▸ | LMNA | P02545 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | MMP1 | P03956 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22300480 | 0.91 | RAB9A (0.62) | TDP1KMT2ASLC6A2SLC6A3RAB9A | |
| SCHEMBL312910 | 0.88 | TDP1 (0.81) | TDP1KMT2ASLC6A2SLC6A3RAB9A | |
| SCHEMBL27999805 | 0.87 | TDP1 (0.51) | TDP1KMT2ASLC6A2SLC6A3RAB9A | |
| SCHEMBL19779313 | 0.87 | KMT2A (0.68) | TDP1KMT2ASLC6A2SLC6A3RAB9A | |
| SCHEMBL25783086 | 0.84 | RAB9A (0.60) | TDP1KMT2ASLC6A2SLC6A3RAB9A | |
| SCHEMBL181934 | 0.83 | TDP1 (0.73) | TDP1KMT2ASLC6A2SLC6A3RAB9A | |
| SCHEMBL56565 | 0.83 | RAB9A (0.82) | TDP1KMT2ASLC6A2SLC6A3RAB9A | |
| Benzyl Benzoate SCHEMBL901058 | 0.82 | KMT2A (1.00) | TDP1KMT2ASLC6A2SLC6A3RAB9A | |
| Benzyl Benzoate SCHEMBL3038 | 0.82 | KMT2A (1.00) | TDP1KMT2ASLC6A2SLC6A3RAB9A | |
| Benzyl Benzoate SCHEMBL8010992 | 0.82 | KMT2A (1.00) | TDP1KMT2ASLC6A2SLC6A3RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322831-A1 | LIGHT-EMITTING DEVICE INCLUDING ORGANOMETALLIC COMPOUND, ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE, AND THE ORGANOMETALLIC COMPOUND | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-10-12 | — | — | US | disclosed |
| US-20230200226-A1 | COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENCE DEVICE, ORGANIC ELECTROLUMINESCENCE DEVICE, AND ELECTRONIC APPARATUS | IDEMITSU KOSAN CO.,LTD. (JP) | 2023-06-22 | — | — | US | disclosed |
| CN-110437068-B | Preparation method of aromatic methylation | 武汉大学 | 2020-11-03 | — | — | CN | disclosed |
| US-10807946-B2 | Antagonists of the glucagon receptor | METABASIS THERAPEUTICS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20190218176-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2019-07-18 | — | — | US | disclosed |
| US-10239829-B2 | Antagonists of the glucagon receptor | METABASIS THERAPEUTICS, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| EP-2590656-B1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX INC (US) | 2017-11-15 | — | — | EP | disclosed |
| EP-2590656-B1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX INC (US) | 2017-11-15 | — | — | EP | disclosed |
| US-20170275246-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | METABASIS THERAPEUTICS, INC. | 2017-09-28 | — | — | US | disclosed |
| US-20170037010-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2017-02-09 | — | — | US | disclosed |
| US-6989389-B2 | Aryl ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES CO. (US) | 2006-01-24 | — | — | US | disclosed |
| US-6953804-B2 | Aryl ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES CO. (US) | 2005-10-11 | — | — | US | disclosed |
| US-20040138248-A1 | Aryl ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-07-15 | — | — | US | disclosed |
| US-20040106640-A1 | Aryl ether substituted imidazoquinolines | COLEY PHARMACEUTICAL GROUP, INC. | 2004-06-03 | — | — | US | disclosed |
| US-6677348-B2 | INDUCE CYTOKINE BIOSYNTHESIS; ANTICARCINOGENIC AGENTS, VIRICIDES | 3M INNOVATIVE PROPERTIES COMPANY | 2004-01-13 | — | — | US | disclosed |
| US-6670372-B2 | Immunomodulators, for inducing cytokine biosynthesis in animals, and in the treatment of viral and neoplastic diseases; imidazo(4,5-c) quinoline-4-amine compounds that have an ether containing substituent at the 1-position | 3M INNOVATIVE PROPERTIES COMPANY | 2003-12-30 | — | — | US | disclosed |
| US-20030212092-A1 | Aryl ether substituted imidazoquinolines | COLEY PHARMACEUTICAL GROUP, INC. | 2003-11-13 | — | — | US | disclosed |
| US-20030212091-A1 | Aryl ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-11-13 | — | — | US | disclosed |
| EP-1341789-A2 | ARYL ETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2003-09-10 | — | — | EP | disclosed |
| WO-2002046189-A2 | ARYL ETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322831-A1 | LIGHT-EMITTING DEVICE INCLUDING ORGANOMETALLIC COMPOUND, ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE, AND THE ORGANOMETALLIC COMPOUND | CRY1, LAGE3, LIG1 | TDP1 2431/4885KMT2A 409/4885SLC6A2 4545/4885 |
| US-20190218176-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | GLP1R, GCGR, GPR119 | TDP1 4552/4885KMT2A 4300/4885SLC6A2 1506/4885 |
| US-20170037010-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A2, SLC34A1, SLC10A2 | TDP1 2592/4885KMT2A 4695/4885SLC6A2 91/4885 |
| US-10239829-B2 | Antagonists of the glucagon receptor | GLP1R, GCGR, GPR119 | TDP1 4534/4885KMT2A 4130/4885SLC6A2 1470/4885 |
| US-20040138248-A1 | Aryl ether substituted imidazoquinolines | IRF3, IFNG, MYD88 | TDP1 3780/4885KMT2A 663/4885SLC6A2 4757/4885 |
| US-20040106640-A1 | Aryl ether substituted imidazoquinolines | IRF3, IFNG, MYD88 | TDP1 3780/4885KMT2A 663/4885SLC6A2 4757/4885 |
| US-20170275246-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | GLP1R, GCGR, GPR119 | TDP1 4549/4885KMT2A 4280/4885SLC6A2 1499/4885 |
| US-10807946-B2 | Antagonists of the glucagon receptor | GLP1R, GCGR, GPR119 | TDP1 4534/4885KMT2A 4122/4885SLC6A2 1447/4885 |
| US-20030212092-A1 | Aryl ether substituted imidazoquinolines | IRF3, IFNG, MYD88 | TDP1 3780/4885KMT2A 663/4885SLC6A2 4757/4885 |
| US-20230200226-A1 | COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENCE DEVICE, ORGANIC ELECTROLUMINESCENCE DEVICE, AND ELECTRONIC APPARATUS | L1CAM, LEF1, PIEZO1 | TDP1 4118/4885KMT2A 1072/4885SLC6A2 3432/4885 |
| US-20030212091-A1 | Aryl ether substituted imidazoquinolines | IRF3, IFNG, MYD88 | TDP1 3780/4885KMT2A 663/4885SLC6A2 4757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.